Vertex and Treefrog Therapeutics Sign a Licensing Agreement & Collaborate to Enhance Production of Vertex’s Cell Therapies for Type-I Diabetes
Shots:
- Vertex will own exclusive license for Treefrog’s cell manufacturing technology, C-Stem
- As per the agreement, TreeFrog will receive $25M as upfront payment, ~$540M for clinical, regulatory and commercial milestones on up to two products, ~215M as milestone payment on development of fully differentiated Islet cells, an equity investment from Vertex and a tiered single digit Royalties; Vertex to also fund future R&D cost related to collaboration
- C-Stem imitates natural microenvironment allowing cell to grow exponentially in 3D and Vertex plans to use C-Stem to scale up production of Insulin producing Pancreatic Islet cells and deliver it to T1D patients
Ref: Vertex | Image: Vertex
Related News:- Vertex to Acquire Alpine Immune Sciences for ~$4.9B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
